Targeting the EGF/HER Ligand-Receptor System in Cancer

Title:Targeting the EGF/HER Ligand-Receptor System in Cancer

Volume: 22 Issue: 39

Author(s): Azucena Esparís-Ogando, Juan Carlos Montero, Joaquín Arribas, Alberto Ocaña and Atanasio Pandiella

Affiliation:

Keywords: Cancer, HER receptors, HER ligands, anti-HER therapies, therapy-resistance.

Abstract: Receptor tyrosine kinases (RTKs) are a superfamily of transmembrane proteins that mediate intracellular signaling by phosphorylating substrate proteins involved in cell proliferation, survival, differentiation or migration. The Human Epidermal growth factor Receptor (HER) family belongs to the RTKs superfamily, and comprises four members: EGFR (epidermal growth factor receptor), HER2, HER3 and HER4. Physiologically, these receptors are activated by the ligands of the EGF family. In solid tumors other mechanisms of activation, such as overexpression or molecular alterations have been reported, and have been linked to tumour initiation/progression. Because of that, several strategies have been developed to target HER receptors and include i) antibody-based therapies using monoclonal antibodies against the extracellular domain of these receptors, and ii) small molecule tyrosine kinase inhibitors (TKIs) against the intracellular kinase domain. In this review we will provide basic information about biological aspects of HER receptors and their ligands as well as the therapeutic strategies to target them. We also summarize general mechanisms of resistance generated in patients to such anti-HER therapies.

Cite this article as:

Esparís-Ogando Azucena, Montero Carlos Juan, Arribas Joaquín, Ocaña Alberto and Pandiella Atanasio, Targeting the EGF/HER Ligand-Receptor System in Cancer, Current Pharmaceutical Design 2016; 22 (39) . https://dx.doi.org/10.2174/1381612822666160715132233